HPS Pharmacies wish to give notice that GlaxoSmithKline and Merck Sharp & Dohme Australia are experiencing an interruption to the supply of hepatitis B vaccines as follows:
Twinrix® Pre-Filled Syringe
Combined hepatitis A & hepatitis B vaccine 720 ELISA units/20µg/ml
Engerix-B® Pre-Filled Syringe
Hepatitis B surface antigen recombinant (yeast) vaccine 20µg/ml
H-B-Vax® II Adult Pre-Filled Syringe
Hepatitis B vaccine (recombinant) 10µg/ml
H-B-Vax® II Paediatric Pre-Filled Syringe
Hepatitis B vaccine (recombinant) 5µg/0.5ml
Twinrix® Junior (combined hepatitis A & hepatitis B vaccine) is not affected by this supply interruption and continues to be available. Normal supplies of Twinrix® Adult are expected to resume on 31st October 2017.
Normal supplies of Engerix-B® are expected to resume on 30th January 2018. Normal supplies of H-B-Vax® II adult and paediatric pre-filled syringes are expected to resume on 31st July 2018.
This supply interruption is affecting all levels of the private market in Australia. However, hepatitis B vaccines remain available for eligible patients under the National Immunisation Program.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, GlaxoSmithKline Australia on 1800 033 109, or Merck Sharp & Dohme Australia on 1800 642 865.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.